Sue Wilson is Senior Research Fellow in the Centre for Neuropsychopharmacology, Division of Brain Sciences.
Sue Wilson’s research has concentrated on the use of EEG and objective sleep measurement in the study of drugs and their neurotransmitter actions in the human brain. She has studied drug effects on sleep in depression, anxiety, substance abuse and sleep disorders such as insomnia and parasomnias. She has also used sleep and daytime EEG to track pharmacodynamic effects of new drugs in healthy volunteers. She recently coordinated the BAP consensus group on treatment of sleep disorders.
et al., 2019, British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update, Journal of Psychopharmacology, Vol:33, ISSN:0269-8811, Pages:923-947
et al., 2018, Using baclofen to explore GABA-B receptor function in alcohol dependence: insights from pharmacokinetic and pharmacodynamic measures, Frontiers in Psychiatry, Vol:9, ISSN:1664-0640
et al., 2018, Antidepressants for insomnia in adults, Cochrane Database of Systematic Reviews, ISSN:1469-493X
et al., 2016, Inverse agonists - what do they mean for psychiatry?, European Neuropsychopharmacology, Vol:27, ISSN:1873-7862, Pages:87-90
et al., 2016, Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation, Human Brain Mapping, Vol:37, ISSN:1097-0193, Pages:3882-3896